Replies to post #159836 on Biotech Values

[mcbio]

Portola: PTLA file $115m IPO

You have any potential interest in this one? Looks like Dew is fairly skeptical on the lead drug in P3, betrixaban, and the related product in Phase 2 (PRT4445). Do you feel the same?

I think the dual JAK/Syk inhibitor for heme onc (B-cell) could be interesting: http://www.portola.com/Product-Pipeline .

I'm curious to find out what fully-diluted market cap will be for this one when it starts trading.

[jq1234]

Portola Set IPO Range

Portola amended its IPO and now plans to sell 6.9 million shares at $13-$16. At the $14.50 mid-point, Portola would raise $100.1 million and be valued at $469.2 million.

http://www.biocentury.com/dailynews/financial/2013-05-07/portola-sets-ipo-range